Stock Events

Stock Events

Scynexis 

$5.30
57
-$0.04-0.84% 20:00 Today
+$0.00+0%20:00After hours

Statistics

Day High
5.44
Day Low
5.18
52W High
10.48
52W Low
3.53
Volume
55,491
Avg. Volume
136,934
Mkt Cap
52.73M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-3.36
-2.03
-0.7
0.63
Expected EPS
-0.72
Actual EPS
N/A

Financials

-41.79%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
20.6MRevenue
-8.61MNet Income

Analyst Ratings

33.00Average Price Target
The highest estimate is 33.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SCYX. It's not an investment recommendation.
Apple
6
AAPL
Amazon
6
AMZN
Microsoft
5
MSFT
Tesla
5
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company that competes with Scynexis in the development of antifungal and antibacterial drugs.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is involved in the development of anti-infective drugs, directly competing with Scynexis' focus on antifungal treatments.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. offers antifungal and antiviral therapies, making it a competitor in the infectious disease market.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a portfolio that includes anti-infective drugs, competing with Scynexis in the pharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments that compete with Scynexis' drug offerings.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. competes in the antifungal space with its own range of products, posing competition to Scynexis.
Novartis
NVS
Mkt Cap292.35B
Novartis AG engages in the development of drugs to treat a wide range of infections, including fungal, competing with Scynexis.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. has a diverse biopharmaceutical portfolio that includes treatments for infections, competing with Scynexis.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a range of anti-infective drugs, making it a competitor in the same market as Scynexis.
Sanofi
SNY
Mkt Cap107.39B
Sanofi operates in the pharmaceutical sector with a focus on anti-infectives among other areas, competing with Scynexis.

About

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Show more...
CEO
David Angulo
Employees
29
Country
United States
ISIN
US8112923094
WKN
000A42CF6

Listings

STU
DE
135.STU
F
DE
135.F
MU
DE
135.MU
MU
DE
135A.MU

0 Comments

Share your thoughts

FAQ

What is Scynexis stock price today?▼
The current price of SCYX is $5.30 USD — it has decreased by -0.84% in the past 24 hours. Watch Scynexis stock price performance more closely on the chart.
What is Scynexis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Scynexis stocks are traded under the ticker SCYX.
Is Scynexis stock price growing?▼
SCYX stock has fallen by -1.67% compared to the previous week, the month change is a -1.85% fall, over the last year Scynexis has showed a -23.75% decrease.
What is Scynexis market cap?▼
Today Scynexis has the market capitalization of 52.73M
When is the next Scynexis earnings date?▼
Scynexis is going to release the next earnings report on November 11, 2026.
What were Scynexis earnings last quarter?▼
SCYX earnings for the last quarter are 0.63 USD per share, whereas the estimation was -0.51 USD resulting in a +224.34% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Scynexis revenue for the last year?▼
Scynexis revenue for the last year amounts to 20.6M USD.
What is Scynexis net income for the last year?▼
SCYX net income for the last year is -8.61M USD.
How many employees does Scynexis have?▼
As of September 04, 2026, the company has 29 employees.
In which sector is Scynexis located?▼
Scynexis operates in the Health & Wellness sector.
When did Scynexis complete a stock split?▼
The last stock split for Scynexis was on June 01, 2026 with a ratio of 1:8.
Where is Scynexis headquartered?▼
Scynexis is headquartered in JERSEY CITY, United States.